| 12.7 0.85 (7.17%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.21 |
1-year : | 17.76 |
| Resists | First : | 13.02 |
Second : | 15.21 |
| Pivot price | 11.9 |
|||
| Supports | First : | 11.71 |
Second : | 10.9 |
| MAs | MA(5) : | 12.34 |
MA(20) : | 11.97 |
| MA(100) : | 11.9 |
MA(250) : | 12.48  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 77.4 |
D(3) : | 76.8 |
| RSI | RSI(14): 54.2 |
|||
| 52-week | High : | 17.79 | Low : | 8.51 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OLMA ] has closed It is unclear right now based on current values. 56.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 12.71 - 12.77 | 12.77 - 12.83 |
| Low: | 11.72 - 11.79 | 11.79 - 11.85 |
| Close: | 12.59 - 12.7 | 12.7 - 12.8 |
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Mon, 09 Sep 2024
Candriam S.C.A. Grows Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Wed, 04 Sep 2024
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Thu, 29 Aug 2024
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth - Simply Wall St
Tue, 06 Aug 2024
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update - StockTitan
Thu, 01 Aug 2024
Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why - Yahoo Finance
Mon, 17 Jun 2024
Olema Pharmaceuticals: Still Merits A Small Holding (NASDAQ:OLMA) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 57 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 100.4 (%) |
| Shares Short | 8,580 (K) |
| Shares Short P.Month | 7,310 (K) |
| EPS | -2.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.97 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.5 % |
| Return on Equity (ttm) | -56.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -92 (M) |
| Levered Free Cash Flow | -45 (M) |
| PE Ratio | -6.23 |
| PEG Ratio | 0 |
| Price to Book value | 3.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|